CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
By running in a marathon or hosting a bake sale, you can make a real difference for our scientists in the fight against cancer and allow them to bring newer immunotherapies to more patients.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Hosted by CRI, EATI, CIMT, and AACR, register today for "Translating Science into Survival," on September 16-19, 2015, in New York City.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Breakthroughs in Cancer Immunotherapy" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
July 7, 2015
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
checkpoint-inhibitor, ipilimumab, melanoma
What’s ahead beyond CTLA-4 and PD-1?
cancer immunotherapy, checkpoint-inhibitor, combination therapy
anti-PD-1, cancer immunotherapy, checkpoint-inhibitor, FDA approval, melanoma
cancer immunotherapy, checkpoint-inhibitor, CTLA-4, events, experimental, scientific leadership
Listen to a radio interview with CRI’s Dr. Jill O’Donnell-Tormey about Keytruda and melanoma.
cancer immunotherapy, checkpoint-inhibitor, interview, melanoma
cancer immunotherapy, checkpoint-inhibitor, PD-1, progress
checkpoint-inhibitor, clinical trials, in the news, lung cancer, patients
checkpoint-inhibitor, CTLA-4, immunotherapy, ipilimumab, James Allison